Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Glesatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AMETHYST
- Sponsors Mirati Therapeutics
- 02 Mar 2018 This trial has been discontinued in Spain.
- 21 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
- 29 Nov 2017 This trial has been suspended in Spain.